|
| Press Releases |
|
 |
|
| Tuesday, November 26, 2024 |
|
|
華住公佈2024年第三季度業績公告 |
| 華住集團有限公司（「華住」或「集團」，納斯達克股份代號：HTHT，聯交所股份代號：1179.HK）公佈2024年第三季度未經審核財務業績，收入和營業額雙增。 more info >> |
|
| Tuesday, August 20, 2024 |
|
|
H World Group Ltd announces Q2 and Interim 2024 Financial Results |
| H World Group Limited ("H World" or "the Group"; NASDAQ: HTHT and HKEX: 1179.HK) announced its unaudited financial results for the second quarter ("Q2 2024") and interim period ended June 30, 2024. more info >> |
|
|
华住公布2024年第二季度及中期财务业绩报告 |
| 华住集团有限公司（「华住」或「集团」，纳斯达克股份代号：HTHT，联交所股份代号：1179.HK）公布截至2024年第二季度及中期未经审核财务业绩公告。 more info >> |
|
|
華住公佈2024年第二季度及中期財務業績報告 |
| 2024年8月20日，香港）華住集團有限公司（「華住」或「集團」，納斯達克股份代號：HTHT，聯交所股份代號：1179.HK）公佈截至2024年第二季度及中期未經審核財務業績公告。 more info >> |
|
| Friday, May 17, 2024 |
|
|
華住公佈2024年第一季度財報 收入增長17.8%优于预期 |
| 華住集團有限公司（「華住」或「集團」，納斯達克股份代號：HTHT.US，港交所股份代號：1179.HK）公佈截至2024年3月31日止第一季度（第一季度）的未經審核財務業績。 more info >> |
|
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation |
| H World Group Limited ("H World" or the "Group", NASDAQ: HTHT.US, HKEX: 1179.HK) announced its unaudited financial results for the first quarter ended March 31, 2024 (Q1). more info >> |
|
| Wednesday, March 20, 2024 |
|
|
華住公佈23年Q4及全年財務業績公告 中國全年RevPAR恢復至2019年水平的122% |
華住集團有限公司（「華住」或「集團」，納斯達克股份代號：HTHT，聯交所股份代號：1179.HK）公佈截至2023年12月31日止第四季度（「2023年第四季度」）及全年的未經審核財務業績。
more info >> |
|
|
H World Announces Q4 and Full Year of 2023 Operating Results, Full Year RevPAR in China Recovered to 122% of the 2019 Level |
| H World Group Limited ("H World" or "the Group", NASDAQ: HTHT and HKEX: 1179) announced its unaudited financial results for the fourth quarter ("Q4 2023") and full year ended December 31, 2023. more info >> |
|
| Friday, November 24, 2023 |
|
|
華住公佈Q3財務業績報告 |
| 華住集團有限公司（「華住」或「集團」，納斯達克股份代號：HTHT，聯交所股份代號：1179.HK）公佈截至2023年9月30日止三個月未經審核財務業績。 more info >> |
|
|
H World Announces Q3 Financial Results |
| H World Group Limited ("H World" or "the Group", NASDAQ: HTHT and HKEX: 1179) announced its unaudited financial results in the third quarter ended September 30, 2023. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System
Aug 18, 2025 14:38 JST
|
|
|
Shoucheng Portfolio Wins 37 Medals at Humanoid Robot Games
Aug 18, 2025 10:35 HKT/SGT
|
|
|
The Business Show Asia 2025 Set to Inspire, Connect, and Transform Businesses
Aug 18, 2025 10:30 HKT/SGT
|
|
|
勇奪12金14銀11銅 首程控股多家被投企業閃耀世界人形機器人運動會
Aug 18, 2025 10:23 HKT/SGT
|
|
|
Anime Tokyo Station Surpasses 200,000 Visitors
Aug 18, 2025 11:00 JST
|
|
|
斩获12金14银11铜 摘得大满贯！首程控股多家被投企业闪耀世界人形机器人运动会
Aug 18, 2025 09:57 HKT/SGT
|
|
|
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
Aug 18, 2025 9:11 JST
|
|
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 16, 2025 15:27 HKT/SGT
|
|
|
WL Delicious Announced 2025 Interim Results
Aug 16, 2025 15:25 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 16, 2025 14:55 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 16, 2025 14:55 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 16, 2025 14:54 HKT/SGT
|
|
|
How Do AI Workflow Automations Work?
Aug 16, 2025 00:00 HKT/SGT
|
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 15, 2025 23:18 HKT/SGT
|
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
